Trials / Completed
CompletedNCT00928525
Imatinib in Patients With Desmoid Tumor and Chondrosarcoma
Open-label Trial of Imatinib in Patients With Desmoid Tumor and Chondrosarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Italian Sarcoma Group · Network
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Imatinib Mesylate is active in diseases - such as Desmoid Tumor and Chondrosarcoma - expressing the receptor for the platelet-derived growth factor (PDGF) both in its isoform alpha and beta
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib Mesylate | 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2009-06-26
- Last updated
- 2023-10-05
Locations
7 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00928525. Inclusion in this directory is not an endorsement.